phosphatidylcholines has been researched along with Cystadenocarcinoma, Serous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avila-Pacheco, J; Clish, CB; Eliassen, AH; Kraft, P; Tworoger, SS; Zeleznik, OA | 1 |
| Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A | 1 |
2 other study(ies) available for phosphatidylcholines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Endometrioid; Case-Control Studies; Ceramides; Cohort Studies; Cystadenocarcinoma, Serous; Female; Humans; Lysophosphatidylcholines; Menopause; Metabolomics; Middle Aged; Ovarian Neoplasms; Phosphatidylcholines; Prospective Studies; Risk; Sphingomyelins | 2020 |
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |